KEATING LAURIE
Transaction: 08/01/2026
OTHER
Change
0
Price
Not reported
Filing
08/03/2026
Type
OTHER
Kalaris Therapeutics Inc
KLRS • Biotechnology
$3.90
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$92.81M
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.02Healthy liquidity · 12.23Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 1:01 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$3.90
Change0.00%
Shares Out23.80M
Market Cap$92.81M
Enterprise Value$-728.51K
52W Range2.31 - 11.88
Beta0.19
P/E-2.10
P/B1.61
P/FCF-2.71
EV/EBITDA0.02
EV/FCF0.02
Price$3.90
Change0.00%
Shares Out23.80M
Market Cap$92.81M
Enterprise Value$-728.51K
52W Range2.31 - 11.88
Beta0.19
P/E-2.10
P/B1.61
P/FCF-2.71
EV/EBITDA0.02
EV/FCF0.02
Earnings Yield-47.69%
FCF Yield-36.85%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.02
Current Ratio12.23
Quick Ratio12.23
Revenue 5Y-100.00%
Target$18.00
Target Upside361.54%
Target Median$17.00
Target Range14.00 - 23.00
Volume56.51K
Avg Volume213.10K
EPS Surprise0.06
Investment DNA
How strong this company looks for long-term investors
47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
90/100
Why this score▼
Manageable debt level · 0.02Healthy liquidity · 12.23Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 1 analyst votes · 2026-09-05
100/100
Bullish
Bullish
1
Hold
0
Bearish
0
Price Target
2026-08-14
Low
$14.00
Mean
$18.00
Median
$17.00
High
$23.00
Insider Transactions
Recent executive and insider activity
KEATING LAURIE
Transaction: 08/01/2026
BUY
Change
+18,000
Price
$3.51
Filing
08/03/2026
Type
BUY
Vandekop Amy O'Leary
Transaction: 07/27/2026
OTHER
Change
+20,000
Price
$6.81
Filing
07/27/2026
Type
OTHER
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| KEATING LAURIE | OTHER | 0 | Not reported | 08/01/2026 | 08/03/2026 |
| KEATING LAURIE | BUY | +18,000 | $3.51 | 08/01/2026 | 08/03/2026 |
| Vandekop Amy O'Leary | OTHER | +20,000 | $6.81 | 07/27/2026 | 07/27/2026 |
| Vandekop Amy O'Leary | OTHER | 0 | Not reported | 07/27/2026 | 07/27/2026 |
| Bayko Liisa Ann | OTHER | 0 | Not reported | 07/20/2026 | 07/20/2026 |
| Bayko Liisa Ann | BUY | +220,000 | $4.00 | 07/20/2026 | 07/20/2026 |
| PATTERSON LEONE D | BUY | +9,000 | $4.72 | 06/03/2026 | 06/04/2026 |
| ADAMIS ANTHONY P | BUY | +9,000 | $4.72 | 06/03/2026 | 06/04/2026 |
| Dybbs Michael | BUY | +9,000 | $4.72 | 06/03/2026 | 06/04/2026 |
| AKKARAJU SRINIVAS | BUY | +9,000 | $4.72 | 06/03/2026 | 06/04/2026 |
| Hallal David | BUY | +9,000 | $4.72 | 06/03/2026 | 06/04/2026 |
| Ferrara Napoleone | BUY | +9,000 | $4.72 | 06/03/2026 | 06/04/2026 |
| Jovan-Embiricos Morana | BUY | +9,000 | $4.72 | 06/03/2026 | 06/04/2026 |
| AKKARAJU SRINIVAS | BUY | +14,937 | Not reported | 05/20/2026 | 05/22/2026 |
| Hagen Brett R | SELL | -1,915 | $6.72 | 03/20/2026 | 03/23/2026 |
| Hagen Brett R | BUY | +60,800 | $6.81 | 03/19/2026 | 03/23/2026 |
| Feinsod Matthew | BUY | +135,000 | $6.81 | 03/19/2026 | 03/20/2026 |
| Gall Matthew | BUY | +95,000 | $6.81 | 03/19/2026 | 03/20/2026 |
| Oxtoby Andrew | BUY | +222,000 | $6.81 | 03/19/2026 | 03/20/2026 |
| AKKARAJU SRINIVAS | BUY | +479,847 | $10.42 | 12/18/2025 | 02/17/2026 |